GlassScriptPhysician profile
Erica M Robles
NPI 1790200368
$4,184.28
in general payments reported to CMS, 2019-2025
23 companies · $1,717 in 2025
The $1,717 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $487 · 2023: $590 · 2024: $1,225 · 2025: $1,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,532.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $737.20 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $709.45 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $414.34 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $355.74 | 2023-2024 | |
| Abbvie INC. | $321.20 | 2022-2025 | |
| Optinose US, INC. | $260.67 | 2024-2025 | |
| Dexcom, INC. | $227.73 | 2024-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Amgen INC. | $208.69 | 2022-2024 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $180.77 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.76 | 2025 | Xifaxan |
| Pfizer INC. | $124.36 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $116.28 | 2022-2024 | Xarelto |
| Glaxosmithkline, LLC. | $116.05 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.02 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $43.45 | 2021-2025 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $35.64 | 2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $30.52 | 2021-2025 | |
| Corcept Therapeutics | $27.24 | 2024 | Korlym |
| Genentech USA, INC. | $23.57 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.62 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $15.72 | 2024 | Capvaxive |
| Phadia US INC. | $15.64 | 2023 | Immunocap |
| Organon LLC | $11.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.